At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Dextromethorphan and quinidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Pilot Study of Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
In Brief
A Phase 2 clinical trial evaluating Dextromethorphan and quinidine and Placebo for Episodic Migraine. Completed, enrolled 76 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesUnited States
CollaboratorsAvanir Pharmaceuticals
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedJun 26, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.0 years ago
Interventions
Dextromethorphan and quinidinedrug
Placebodrug